Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side Chains
Citations Over TimeTop 12% of 1999 papers
Abstract
Dihydropyrimidinones, such as 1, represent a novel class of alpha(1a) adrenoceptor antagonists with potential for the treatment of benign prostatic hyperplasia (BPH) (see part 1 of this series). Analysis of the metabolites of 1 revealed that 4-methoxycarbonyl-4-phenylpiperidine is formed as the major metabolite and is an agonist at the mu-opioid receptor. To circumvent any potential liability resulting from the metabolite, we decided to identify alternate templates devoid of agonist activity at the mu-opioid receptor to replace the 4-methoxycarbonyl-4-phenylpiperidine moiety. The present study describes the synthesis and SAR of dihydropyrimidinones linked to substituted 4-phenylpiperazine containing side chains. Compound (+)-38 was identified as a lead compound with a binding and functional profile comparable to that of 1. The putative metabolite 2-carboxamidophenylpiperazine has negligible affinity for the mu-opioid receptor.
Related Papers
- → Recent advances in selective opioid receptor agonists and antagonists(2003)163 cited
- → Are μ-opioid receptor polymorphisms important for clinical opioid therapy?(2005)144 cited
- → Receptor‐selective changes in µ‐, δ‐ and κ‐opioid receptors after chronic naltrexone treatment in mice(2003)74 cited
- → Evidence for Multiple Opioid Receptors in the Human Posterior Pituitary(1996)29 cited
- → Synthesis and biological properties of new 1β-methylcarbapenems containing heteroaromatic thioether moiety(2001)12 cited